🔗 Visit the ClinicalTrials.gov page for NCT00082758
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. | J Clin Oncol | 2010 | 1.57 |
| 2 | Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. | BioDrugs | 2015 | 0.87 |
| 3 | Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. | Semin Oncol | 2014 | 0.77 |
| 4 | Novel antibody-based proteins for cancer immunotherapy. | Cancers (Basel) | 2011 | 0.75 |